The utility of 2-[18F]FDG-PET/CT maximum SUV versus CT attenuation for directing bone biopsies.
The utility of 2-[18F]FDG-PET/CT maximum SUV versus CT attenuation for directing bone biopsies.
复制标题
2-[18F]FDG-PET/CT 最大 SUV 与 CT 衰减在指导骨活检中的用途。
DOI：
10.1007/s00330-021-07770-8
复制
发表时间：
2021
影响因子：
5.9
通讯作者：
Ashok,SSharon
中科院分区：
文献类型：
--
作者：
Sebro,Ronnie;Ashok,SSharon
ObjectivesThis study aims to comparison the accuracy of PET/CT parameters with CT parameters for directing bone biopsies.MethodsThe study was a IRB-approved retrospective study of 388 patients who performed both 2-[18F] FDG PET/CT and CT within 6 weeks before a bone biopsies. MethodsThe study was a IRB-approved retrospective study of 388 patients who performed both 2-[18F] FDG PET/CT and CT before a bone biopsies.年龄、性别、肿瘤类型、病变长度、SUVmax、肿瘤/肝脏（T/L）比值、CT衰减、病变与正常骨的CT衰减差异（Δ CT衰减）和绝对Δ CT衰减被用作预测因素。DeLong检验用于比较受试者工作特征（ROC）currents.ResultsWe审查了388例患者的数据。其中，295例患者接受了骨病变活检，93例患者接受了骨髓抽吸/活检。较大骨病变（p= 0.033）和SUVmax较高的骨病变（p= 0.005）的活检更可能显示恶性肿瘤。对于骨病变，SUVmax的ROC曲线（AUC = 0.6827）优于Δ CT衰减的ROC曲线（AUC = 0.5766，p = 0.032）和绝对Δ CT衰减（AUC = 0.5491，p = 0.006），但并不显著优于CT衰减的ROC曲线AUC = 0.5894，p = 0.061; T/L比值AUC = 0.6778，p = 0.774。阈值SUVmax为5.25预测骨病变活检中恶性肿瘤的准确性为0.713，敏感性为0.766，特异性为0.549。这些变量均不能预测骨髓活检中的恶性肿瘤（p> 0.05）。结论与CT参数相比，代谢性2-[18 F]FDG PET/CT参数对计划骨活检具有更大的临床影响。关键点·与CT测量相比，2-[18 F]FDG PET/CT测量（SUVmax）对计划骨活检具有更大的临床影响。·病变相对于正常骨的CT衰减变化及其绝对值均不是恶性肿瘤的显著预测因子。·2-[18F]FDG PET/CT可能具有临床益处，并在指导骨活检中发挥额外作用。
ObjectivesThis study aimed to compare the accuracy of PET/CT parameters with CT parameters for directing bone biopsies.MethodsThe study was an IRB-approved retrospective study of 388 patients who underwent both 2-[18F] FDG PET/CT and CT within 6 weeks before a bone biopsy. Age, sex, cancer type, lesion length, SUVmax, tumor to liver (T/L) ratio, CT attenuation, difference in CT attenuation between the lesion and normal bone (delta CT attenuation), and the absolute delta CT attenuation were used as predictors.Ttests and chi-squared tests were used to compare variables. DeLong’s test was used to compare receiver operator characteristic (ROC) curves.ResultsWe reviewed the data from 388 patients. Of these, 295 patients had bone lesion biopsies, and 93 patients had bone marrow aspirations/biopsies. Biopsies of larger bone lesions (p= 0.033) and bone lesions with higher SUVmax(p= 0.005) were more likely to show malignancy. For bone lesions, the ROC curve for the SUVmax(AUC = 0.6827) was better than the ROC curves for delta CT attenuation (AUC = 0.5766,p= 0.032) and absolute delta CT attenuation (AUC = 0.5491,p= 0.006), but not significantly better than the ROC curves for CT attenuation (AUC = 0.5894,p= 0.061) and T/L ratio (AUC = 0.6778,p= 0.774). A threshold SUVmaxof 5.25 had an accuracy of 0.713, sensitivity of 0.766, and specificity of 0.549 to predict malignancy in bone lesion biopsies. None of these variables predicted malignancy in bone marrow biopsies (p> 0.05 for all).ConclusionsMetabolic 2-[18F]FDG PET/CT parameters have more clinical impact for planning bone biopsies as compared to CT parameters.Key Points• The 2-[18F]FDG PET/CT measurement (SUVmax) has more clinical impact for planning bone biopsies as compared to CT measurements.• Neither the change in CT attenuation of the lesion relative to normal bone nor the absolute value of this change was a significant predictor of malignancy.• 2-[18F]FDG PET/CT may have clinical benefit and an additional role in directing bone biopsies.